Literature DB >> 11389810

Transitional cell carcinoma of the bladder: new approaches to the treatment of advanced disease.

D P Petrylak.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11389810     DOI： 10.1007/s11912-001-0076-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  19 in total

Review 1.  Paclitaxel in the treatment of advanced urothelial cancer.

Authors:  D F Bajorin
Journal:  Oncology (Williston Park)       Date:  2000-01       Impact factor: 2.990

2.  Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

Authors:  C N Sternberg; P de Mulder; J H Schornagel; C Theodore; S D Fossa; A T van Oosterom; J A Witjes; M Spina; C J van Groeningen; B Duclos; J T Roberts; C de Balincourt; L Collette
Journal:  Eur J Cancer       Date:  2005-12-05       Impact factor: 9.162

3.  Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma.

Authors:  R S Witte; P Elson; B Bono; R Knop; R R Richardson; R Dreicer; P J Loehrer
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

Authors:  J A McCaffrey; S Hilton; M Mazumdar; S Sadan; W K Kelly; H I Scher; D F Bajorin
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

Review 5.  Review and outlook for the role of paclitaxel in urothelial carcinoma.

Authors:  D J Vaughn
Journal:  Semin Oncol       Date:  1999-02       Impact factor: 4.929

6.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

7.  Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor.

Authors:  C J Logothetis; F H Dexeus; A Sella; R J Amato; R G Kilbourn; L Finn; J U Gutterman
Journal:  J Natl Cancer Inst       Date:  1990-04-18       Impact factor: 13.506

8.  Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.

Authors:  M J Moore; I F Tannock; D S Ernst; S Huan; N Murray
Journal:  J Clin Oncol       Date:  1997-12       Impact factor: 44.544

9.  Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.

Authors:  A D Seidman; H I Scher; J L Gabrilove; D F Bajorin; R J Motzer; M O'Dell; T Curley; D D Dershaw; S Quinlivan; Y Tao
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

10.  Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial.

Authors:  C J Logothetis; L D Finn; T Smith; R G Kilbourn; J A Ellerhorst; A A Zukiwski; A Sella; S M Tu; R J Amato
Journal:  J Clin Oncol       Date:  1995-09       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.